切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (02) : 118 -120. doi: 10.3877/cma.j.issn.1674-0807.2019.02.011

所属专题: 文献

综述

前哨淋巴结微转移与腋窝淋巴结复发关系的研究进展
解新鹏1, 刘维芳1, 张宇1, 吴迪1, 张秀祥1, 徐格格1, 杨霞1, 石爱平1,()   
  1. 1. 130021 长春,吉林大学白求恩第一医院乳腺外科
  • 收稿日期:2018-07-19 出版日期:2019-04-01
  • 通信作者: 石爱平

Relationship between sentinel lymph node micrometastasis and axillary lymph node recurrence

Xinpeng Xie1, Weifang Liu1, Yu Zhang1   

  • Received:2018-07-19 Published:2019-04-01
引用本文:

解新鹏, 刘维芳, 张宇, 吴迪, 张秀祥, 徐格格, 杨霞, 石爱平. 前哨淋巴结微转移与腋窝淋巴结复发关系的研究进展[J]. 中华乳腺病杂志(电子版), 2019, 13(02): 118-120.

Xinpeng Xie, Weifang Liu, Yu Zhang. Relationship between sentinel lymph node micrometastasis and axillary lymph node recurrence[J]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(02): 118-120.

乳腺癌是女性最常见的恶性肿瘤,而腋窝淋巴结的转移状态与乳腺癌患者的预后相关。自从开展乳腺癌前哨淋巴结活组织检查以来,一部分乳腺癌患者因前哨淋巴结阴性而免除了腋窝淋巴结清扫,而另一部分患者因前哨淋巴结微转移选择术后放射治疗或是化疗以替代腋窝淋巴结清扫,从而减少了患侧上肢淋巴水肿、运动障碍以及感觉障碍等并发症的发生。近年来,少部分前哨淋巴结微转移患者发生了不同程度的腋窝淋巴结复发。对此,部分学者认为前哨淋巴结微转移患者即使不做腋窝淋巴结清扫,腋窝淋巴结复发率也未见明显增加;但部分学者则认为前哨淋巴结微转移应被视为腋窝淋巴结转移,残留的肿瘤病灶能增加腋窝淋巴结复发率,因此应行腋窝淋巴结清扫术。对于前哨淋巴结微转移的处理方式,国内外专家尚未得出一致的结论。目前众多研究者仍在不懈地进行相关临床试验及大数据分析,旨在为前哨淋巴结微转移患者寻求更佳的治疗方案。

[1]
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894[J]. Ann Surg, 1894, 20(5):497-555.
[2]
Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial [J].Ann Surg, 2016, 264(3):413-420.
[3]
Vijayaraghavan GR, Vedantham S, Kataoka M, et al. The relevance of ultrasound imaging of suspicious axillary lymph nodes and fine-needle aspiration biopsy in the post-ACOSOG Z11 era in early breast cancer[J].Acad Radiol, 2017, 24 (3):308-315.
[4]
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial [J].JAMA, 2017, 318(10):918-926.
[5]
Wetzig N, Gill PG, Espinoza D, et al. Sentinel-lymph-node-based management or routine axillary clearance five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema[J].Ann Surg Oncol, 2017, 24(4):1064-1070.
[6]
张晓东,梁运升.乳腺癌前哨淋巴结检测及其临床意义[J].解放军预防医学杂志,2018, 36(4):477-479.
[7]
Ibis K, Ozkurt S, Kucucuk S, et al. Comparison of pathological prognostic stage and anatomic stage groups according to the updated version of the American Joint Committee on Cancer (AJCC) breast cancer staging 8th edition [J].Med Sci Monit, 2018, 24:3637-3643.
[8]
Tallet A, Lambaudie E, Cohen M, et al. Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy [J]. World J Clin Oncol, 2016, 7(2): 243-252.
[9]
Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial[J]. J Clin Oncol, 2014, 32(32):3600-3606.
[10]
Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells [J].Ann Surg, 2012, 255(1):116-121.
[11]
Francissen CM, Dings PJ, van Dalen T, et al. Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature [J]. Ann Surg Oncol, 2012, 19(13):4140-4149.
[12]
de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer [J]. N Engl J Med, 2009, 36(1): 653-663.
[13]
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel node micrometastases (IBCSG 23-01): a phase 3 randomized controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
[14]
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer[J].N Engl J Med, 2003, 349(6):546-553.
[15]
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J].Ann Surg, 2010, 252(3):426-432.
[16]
Belmonte R, Messaggi-Sartor M, Ferrer M, et al. Prospective study of shoulder strength, shoulder range of motion, and lymphedema in breast cancer patients from pre-surgery to 5 years after ALND or SLNB [J].Support Care Cancer, 2018, 26 (9): 3277-3287.
[17]
Siotos C, Sebai ME, Wan EL, et al. Breast reconstruction and risk of arm lymphedema development: A meta analysis[J].J Plast Reconstr Aesthet Surg, 2018, 71(6):807-818.
[18]
Gratzon A, Schultz J, Secrest K, et al.Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy[J].Ann Surg Oncol, 2017, 24(6):1475-1481.
[19]
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J].Lancet Oncol, 2010, 11(10):927-933.
[20]
Van Zee KJ, Kattan MW. Validating a predictive model for presence of additional disease in the non-sentinel lymph nodes of a woman with sentinel node positive breast cancer [J].Ann Surg Oncol, 2007, 14(8):2177-2178.
[21]
Malter W, Hellmich M, Badian M, et al. Factors predictive of sentinel lymph node involvement in primary breast cancer [J].Anticancer Res, 2018, 38(6):3657-3662.
[22]
Nowikiewicz T, Zegarski W, Pagacz K, et al. The current application of ACOSOG Z0011 trial results: Is further implementation of sentinel lymph node intra-operative histopathological examination mandatory in breast cancer patients-a single-centre analysis [J].Neoplasma, 2018, 65(3):449-454.
[23]
Geertsema D, Gobardhan PD, Madsen EV, et al. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy[J].Ann Surg Oncol, 2010, 17(10):2690-2695.
[24]
Jakub JW, Bryant K, Huebner M, et al. The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes[J].Ann Surg Oncol, 2011, 18(1):86-93.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(08): 844-848.
[2] 邵华, 那子悦, 荆慧, 李博, 王秋程, 程文. 术前经皮超声造影对乳腺癌腋窝前哨淋巴结转移及负荷的诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 849-853.
[3] 孙帼, 谢迎东, 徐超丽, 杨斌. 超声联合临床特征的列线图模型预测甲状腺乳头状癌淋巴结转移的价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 734-742.
[4] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[5] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[6] 江艺, 张小进, 沈佳佳. 胆囊癌伴肝多发转移手术治疗(腹腔镜下胆囊癌切除+淋巴结清扫+肝Ⅴ、Ⅵ、Ⅶ段切除)[J]. 中华普通外科学文献(电子版), 2023, 17(06): 412-412.
[7] 燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[8] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[9] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[10] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[11] 肖体先, 刘骞, 宋京海. 乳房外Paget病脾转移一例报告[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 717-719.
[12] 杨红杰, 张智春, 孙轶. 直肠癌淋巴结转移诊断研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 512-518.
[13] 李英茹, 李非, 张玉茹, 刘莉婷. 单点-点压法注射纳米碳在腹腔结肠癌根治术中应用探讨[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 414-417.
[14] 王小红, 钱晶, 翁文俊, 周国雄, 朱顺星, 祁小鸣, 刘春, 王萍, 沈伟, 程睿智, 秦璟灏. 巯基丙酮酸硫基转移酶调控核因子κB信号介导自噬对重症急性胰腺炎大鼠的影响及机制[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 422-426.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要